

Published in final edited form as:

Arch Gen Psychiatry. 2011 September ; 68(9): 901–910. doi:10.1001/archgenpsychiatry.2011.50.

Using Polymorphisms in *FKBP5* to Define Biologically Distinct Subtypes of Posttraumatic Stress Disorder:

Evidence From Endocrine and Gene Expression Studies

Dr. Divya Mehta, PhD, Dr. Mariya Gonik, PhD, Dr. Torsten Klengel, MD, Ms. Monika Rex-Haffner, Dr. Andreas Menke, MD, Ms. Jennifer Rubel, Ms. Kristina B. Mercer, MPH, Dr. Benno Pütz, PhD, Dr. Bekh Bradley, PhD, Dr. Florian Holsboer, MD, PhD, Dr. Kerry J. Ressler, MD, PhD, Dr. Bertram Müller-Myhsok, MD, and Dr. Elisabeth B. Binder, MD, PhD Max-Planck Institute of Psychiatry, Munich, Germany (Drs Mehta, Gonik, Klengel, Menke, Pütz, Holsboer, Müller-Myhsok, and Binder and Mss Rex-Haffner and Rubel); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine (Drs Bradley, Ressler, and Binder), VA Medical Center (Dr Bradley), and Yerkes National Primate Research Center (Dr Ressler), Atlanta, Georgia; and Howard Hughes Medical Institute, Chevy Chase, Maryland (Ms Mercer and Dr Ressler)

Abstract

Context—Polymorphisms in the gene encoding the glucocorticoid receptor (GR) regulating co-chaperone *FKBP5* have been shown to alter GR sensitivity and are associated with an increased risk to develop posttraumatic stress disorder (PTSD).

Objective—To investigate interactions of the *FKBP5* single-nucleotide polymorphism rs9296158 and PTSD symptoms on baseline cortisol level, low-dose dexamethasone suppression, and whole-blood gene expression.

Design—Association of *FKBP5* genotypes and PTSD symptoms with endocrine measures and genome-wide expression profiles.

Setting—Waiting rooms of general medical and gynecological clinics of an urban hospital at Emory University.

Participants—The 211 participants were primarily African American (90.05%) and of low socioeconomic status and had high rates of trauma and PTSD.

Main Outcome Measures—Baseline and post-dexamethasone suppression cortisol measures and gene expression levels.

Results—In our endocrine study, we found that only risk allele A carriers of rs9296158 showed GR supersensitivity with PTSD; in contrast, baseline cortisol levels were decreased in PTSD only

©2011 American Medical Association. All rights reserved.

Correspondence: Elisabeth B. Binder, MD, PhD, Max Planck Institute of Psychiatry, Kraepelinstrasse 2, Munich 80804, Germany (binder@mpipsykl.mpg.de).

Online-Only Material: The eFigures and eTables are available at <http://www.archgenpsychiatry.com>.

Financial Disclosure: Part of this work was funded by NeuroNova. Drs Binder, Menke, and Holsboer have filed a patent application as inventors of “Means and Methods for Diagnosing Predisposition for Treatment Emergent Suicidal Ideation (TESI)” (European application 08016477.5; international application PCT/EP2009/061575), and Drs Binder, Müller-Myhsok, and Holsboer have filed a patent application as inventors of “FKBP5: A Novel Target for Antidepressant Therapy” (international publication WO 2005/054500). Dr Holsboer is a founder and shareholder of Affectis Pharmaceuticals. Within the last 3 years, Dr Ressler has received research funding support from Lundbeck, and he has an unrelated role as cofounder of Extinction Pharmaceuticals for development of N-methyl-D-aspartate-based therapeutics. Dr Binder has current grant support from PharmaNeuroBoost.

in patients with the GG genotype. Expression of 183 transcripts was significantly correlated with PTSD symptoms after multiple testing corrections. When adding *FKBP5* genotype and its interaction with PTSD symptoms, expression levels of an additional 32 genes were significantly regulated by the interaction term. Within these 32 genes, previously reported PTSD candidates were identified, including *FKBP5* and the *IL18* and *STAT* pathways. Significant overrepresentation of steroid hormone transcription factor binding sites within these 32 transcripts was observed, highlighting the fact that the earlier-described genotype and PTSD-dependent differences in GR sensitivity could drive the observed gene expression pattern. Results were validated by reverse transcriptase–polymerase chain reaction and replicated in an independent sample (N=98).

Conclusions—These data suggest that the inheritance of GR sensitivity–moderating *FKBP5* polymorphisms can determine specific types of hypothalamic–pituitary–adrenal axis dysfunction within PTSD, which are also reflected in gene-expression changes of a subset of GR-responsive genes. Thus, these findings indicate that functional variants in *FKBP5* are associated with biologically distinct subtypes of PTSD.

Posttraumatic stress disorder (PTSD) is a severely debilitating psychiatric condition characterized by persistent symptoms of intrusive reexperiencing, avoidance, and hyperarousal following exposure to a traumatic event. Although a lifetime trauma incidence of 40% to 90% in the general population has been reported, the overall lifetime prevalence for PTSD ranges between 7% and 12%.^{1,2} This suggests that individuals with a specific genetic susceptibility might have a higher risk of developing PTSD after experiencing traumatic events. Twin and family studies have provided evidence for a genetic component in the development of PTSD.^{3–5}

While studies investigating main genetic effects associated with PTSD have yielded inconsistent findings,^{6–8} there is growing evidence supporting the role of gene×environment interactions in PTSD.⁹ For example, polymorphisms in the serotonin transporter gene as well as in the glucocorticoid receptor–regulating co-chaperone FK506 binding protein 5 (*FKBP5*) have been found in more than 1 cohort to have significant interactions with environmental exposure on risk for PTSD.^{9–11} Additionally, the syndrome of PTSD, as with many other psychiatric disorders, is clinically variable. The identification of biologically distinct subsets of patients with PTSD would provide an important tool for improving our mechanistic, diagnostic, and therapeutic approaches to PTSD. This study is predicated on the possibility that there are subtypes of PTSD that can be differentiated based on differential physiological stress reactivity that may, in part, be genetically determined.

The stress hormone system, or hypothalamus–pituitary–adrenal (HPA) axis, is likely an important mediator of such gene×environment interactions because it is activated by traumatic events and dysregulated in a number of psychiatric disorders, including PTSD.¹² In fact, HPA axis dysfunction with higher glucocorticoid receptor (GR) sensitivity is described to be one of the endocrine hallmarks of PTSD.¹³ A number of studies have shown altered stress hormone/cortisol levels in PTSD and enhanced GR sensitivity as measured by a low-dose dexamethasone suppression test as well as ex vivo binding assays.^{14–17}

Overall, these studies reflect a sensitization of the HPA axis in response to exposure to stressors, with changes in GR function playing a critical role in the pathophysiology of PTSD. The function of the GR is dependent on a large molecular complex, including chaperones and co-chaperones as well as coactivators and corepressors.^{18,19} One of the co-chaperones strongly regulating GR function is *FKBP5*, which is part of the mature GR heterocomplex and is known to regulate GR sensitivity.²⁰ When bound to the steroid receptor, *FKBP5* decreases its affinity for the ligand and prevents translocation to the nucleus.^{20,21} By being a modulator of GR sensitivity, *FKBP5* is an interesting candidate

gene for PTSD. In fact, 2 studies so far have reported interactions of functional polymorphisms within *FKBP5* with early trauma to predict adult PTSD.^{10,11} In addition to these interaction effects on PTSD symptoms, we have also reported *FKBP5* genotype-dependent difference in GR sensitivity in PTSD.¹⁰ Only patients with PTSD carrying the risk alleles displayed increased GR sensitivity, suggesting that endocrine changes observed with PTSD might be restricted to a genetically defined subset of patients.

In our previous report, rs9296158 showed the strongest interaction with early trauma on PTSD symptoms¹⁰ and was chosen as a tagging single-nucleotide polymorphism (SNP) for a functional haplotype that includes rs1360780 and rs3800373. Within this haplotype, risk alleles for PTSD are associated with an increased induction of *FKBP5* messenger RNA by glucocorticoids, increased *FKBP5* protein levels, and, as a consequence, a decrease in GR sensitivity and negative feedback regulation of the HPA axis in healthy controls.^{10,22,23} Genotype-dependent endocrine and messenger RNA effects in PTSD are less well studied.

We hypothesized that functional polymorphisms within *FKBP5* are associated with differential GR sensitivity, which together may define biologically distinct subsets of patients with PTSD. To test this, we investigated interactions of the *FKBP5* SNP rs9296158 and PTSD symptoms on baseline cortisol level, low-dose dexamethasone suppression, and whole-blood gene expression in a highly traumatized, low-income, primarily African American cohort with high rates of PTSD.^{24,25}

METHODS

SAMPLES

The participants were a subset of a larger study investigating the contribution of genetic and environmental factors in PTSD^{10,25,26} and they had each experienced at least 1 traumatic event. Individuals were recruited between 2007 and 2010 at Grady Memorial Hospital, Atlanta, Georgia.²⁴ All study procedures were approved by the institutional review boards of Emory University School of Medicine and Grady Memorial Hospital and all subjects gave written informed consent to the study.

Of the 219 participating individuals, 211 had available serum samples for baseline cortisol level only, while 115 also had cortisol measures after low-dose dexamethasone suppression. All individuals had DNA samples from whole blood or saliva and whole-blood RNA. Of 219 individuals, 10 samples were excluded from RNA analysis because of a low RNA integrity number (<5.0).²⁷ Of 209 individuals, 111 individuals served as discovery samples and 98 served as replication samples for gene expression (eFigure 1 and eTable 1, <http://www.archgenpsychiatry.com>).

PSYCHOLOGICAL ASSESSMENTS

PTSD Symptom Scale—The PTSD Symptom Scale (PSS) was used as a measure of PTSD symptoms.²⁸ The PSS frequency items were summed to obtain a continuous measure ranging from 0 to 48. The mean (SD) PSS score across all 219 individuals was 13.12 (12.33) points, with values more than 20.0 usually considered to show clinically significant PTSD symptoms. Application of the *DSM-IV* criteria for PTSD to the PSS frequency items was used to create a proxy variable for PTSD diagnosis status.

Clinician-Administered PTSD Scale—The Clinician-Administered PTSD Scale (CAPS) score was available for a subset of 156 of the 219 individuals.²⁹ The mean (SD) current CAPS score in the 156 individuals was 39.95 (40.38). There was a significant correlation between PSS score and current CAPS score (Pearson $r=0.657$; $P<.01$).

Beck Depression Inventory—The Beck Depression Inventory was administered to measure depression symptoms.³⁰ In this sample, the Beck Depression Inventory score ranged from 0 to 55 (mean [SD], 14.26 [11.63]). Values more than 18.0 are considered to show clinically relevant depressive symptoms.

TRAUMA EXPOSURE MEASUREMENTS

Trauma Events Inventory—The Trauma Events Inventory was the primary measure of non-child abuse trauma in this study.³¹ Total numbers of different types of non-child abuse trauma among the participants were summed. The mean (SD) score for non-child abuse trauma reported within this study sample was 3.90 (2.61).

Childhood Trauma Questionnaire—The Childhood Trauma Questionnaire was used as a continuous measure of child abuse.³² The Childhood Trauma Questionnaire score ranged from 25 to 111, with a mean (SD) of 42.20 (18.59).

Substance Abuse—Open-ended questions as well as the Kreek-McHugh-Schluger-Kellogg Scale were used to quantify self-exposure to opiates, cocaine, alcohol, and tobacco³³ and to assess overall current and past substance use.

Dexamethasone Suppression Test—The subjects were characterized using a low-dose dexamethasone suppression test. After patients fasted, blood was collected between 8 and 9 AM for baseline serum cortisol measurements. The subjects received 0.5 mg of dexamethasone orally at 11 PM. Blood was collected between 8 and 9 AM the next day for serum cortisol measurement after dexamethasone stimulation. Serum cortisol concentration was measured with a commercial radioimmunoassay kit (Diagnostic Systems Laboratories, Webster, Texas).

DNA Extraction and SNP Genotyping—DNA was extracted from whole blood or saliva collected in Oragene saliva kits (DNA Genotek, Ottawa, Ontario, Canada) using the Qiagen M48 automated extraction system (Qiagen, Valencia, California). We genotyped rs9296158 using a TaqMan-based assay, as described before.¹⁰

RNA Extraction and Microarray Procedures for the Atlanta PTSD Samples—After patients fasted, whole blood was collected between 8 and 9 AM in Tempus RNA tubes (Applied Biosystems, Darmstadt, Germany) for baseline cortisol measurements. RNA was isolated using the Versagene kit (Gentra Systems, Minneapolis, Minnesota) and quantified using the NanoPhotometer (Implen, Westlake Village, California) and quality checks were performed on the Agilent Bioanalyzer (Agilent Technologies, Santa Clara, California). RNA was not globin reduced since our preliminary data showed that although globin reduction increased the sensitivity, it altered the expression of nonglobin transcripts in a nonreproducible manner (data not shown). Two hundred fifty nanograms of total RNA were reverse transcribed to complementary DNA, converted to complementary RNA, and biotin labeled using the Ambion kit (AMIL1791; Applied Biosystems). Seven hundred fifty nanograms of complementary RNA were hybridized to Illumina HT-12 version 3.0 arrays (Illumina, San Diego, California) and incubated overnight (16 hours) at 55°C. Arrays were washed, stained with Cy3-labeled streptavidin, dried, and scanned on the Illumina Bead-Scan confocal laser scanner.

Quantitative Polymerase Chain Reaction Procedures—For validation and replication of the results, complementary DNA was synthesized from 200 ng of total RNA using Superscript II Reverse Transcriptase (Invitrogen, Darmstadt, Germany). Quantitative polymerase chain reaction (qPCR) was performed using the Universal Probe Library for

FKBP5, *IL18R1*, and *TBP* on the Roche LightCycler 480 (Roche Applied Science, Penzberg, Germany). Assays were designed using Probe Finder Software (Roche Applied Science) and run in duplicate according to the manufacturer's protocol, except for a total reaction volume of 10 μ L (eTable 2).

STATISTICAL ANALYSIS

Microarray Data Analysis—Raw microarray scan files were exported using the Illumina BeadStudio program and loaded into R for downstream analysis (<http://www.R-project.org>). The data were transformed and normalized using the variance-stabilizing normalization.³⁴ Of 48 804 probes present on the Human HT-12 version 3.0 assays, probes were selected that fulfilled the criteria of the Illumina probe detection *P* value of <.01 in 5% of the individuals. A total of 15 583 probes passing the filter criteria were used for subsequent analysis. Association analysis was performed in R. General linear models were constructed using the quantitative PSS scores, rs9296158 A carrier genotypic model, and interactions between the 2 as predictors, controlling for age and sex. The significance of association was estimated by a 2-tailed *P* value corresponding to the *t* ratio based on a *t* reference distribution. To assess the contributions of model covariates, pairwise comparison between the full and reduced models was performed using an analysis of variance *F* test. The results were corrected for multiple testing using the permutation of regressor residuals test implemented in the R package glmperm (<http://cran.r-project.org/web/packages/glmperm/index.html>). For each transcript, 10 000 permutations were performed. The permutation of regressor residuals test permutes the residuals from the linear regression models using the shuffle-Z method for permutation.³⁵ Repeated-measures analysis was performed in SPSS (SPSS Inc, Chicago, Illinois) using the analysis of variance design. The Huynh-Feldt method was applied to correct for potential violations of the sphericity assumption.³⁶

The BiblioSphere data mining software from Genomatix was used for pathway analysis of transcripts.³⁷ BiblioSphere is a data-mining solution for extracting and studying gene relationships from literature databases and genome-wide promoter analysis.³⁸ The signal transduction association filter with the highest specificity was used where 2 genes were co-cited in a sentence containing a pathway-associated term, with at least 1 of the co-cited genes bearing a Genomatix signal transduction pathway annotation used for the pathway (<http://www.genomatix.de>). The JASPAR CORE database via the cREMaG interface (<http://149.156.177.116/cremag/>) was used to assess the distribution of steroid receptor binding sites.³⁹

qPCR Data Analysis—Raw data from the Roche LightCycler 480 System were extracted using LinRegPCR software.⁴⁰ The crossing thresholds (C_T) from the technical replicates were averaged across all samples. The transcripts were normalized to housekeeping gene *TBP*. Normalized ΔC_T values were converted into the linear form by $2^{-\Delta C_T}$ transformation⁴¹. The transformed ΔC_T values were regressed against the PSS score, rs9296158, and their interaction, while adjusting for age and sex, in R. For calculation of correlations between expression and PSS scores, negative correlations of the ΔC_T were used to make the direction of effect comparable with the microarray data.

RESULTS

DESCRIPTIVE ANALYSIS OF INDIVIDUALS USED FOR ENDOCRINE ANALYSIS AND MICROARRAY ANALYSIS

Phenotypic characteristics of the 211 individuals used for endocrine analysis and 111 individuals used for microarray analysis are shown in Table 1. For comparisons, individuals

were separated into groups of PTSD and non-PTSD based on *DSM-IV* criteria for PTSD using the responses to the PSS interview.

No differences in age, sex, ethnicity, and substance abuse were observed between the groups ($P > .05$) in both samples. There were no significant differences in adult trauma exposure ($P = .11$) in the microarray data set, but there was a significant difference in the endocrine data set ($P = .001$). Differences in child abuse were significant ($P < .001$ for the endocrine data set; $P = .004$ for the microarray data set). The severity of the PTSD symptoms measured by the PSS and current CAPS was significantly higher among individuals in the PTSD group ($P < .001$ for PSS score and $P < .001$ for CAPS score in the endocrine data set; $P < .001$ for PSS score and $P < .001$ for CAPS score in the microarray data set). Individuals with PTSD had higher Beck Depression Inventory scores than those without PTSD ($P < .001$ for the endocrine data set and $P < .001$ for the microarray data set). To determine whether the comorbidity between PTSD and depression would lead to multicollinearity, diagnostic tests for variance inflation factor and tolerance were estimated using SPSS. The variance inflation factor was 1.1 and the tolerance was 0.903, indicating no evidence for multicollinearity.

BASELINE CORTISOL LEVEL AND DEXAMETHASONE SUPPRESSION IN THE ATLANTA COHORT

Previously, we reported a possible genotype-dependent difference in the effects of PTSD on GR sensitivity ($n=80$), with higher GR sensitivity only in patients with PTSD carrying the risk allele.¹⁰ We now reinvestigated the effects of both PTSD symptoms and rs9296158 genotype in a second larger independent sample ($n=211$ for baseline cortisol level and $n=115$ for the dexamethasone suppression test).

Baseline Cortisol Level—We first regressed baseline cortisol levels against the PSS score, *FKBP5* SNP rs9296158 A carrier status, and their interaction term, adjusting for age and sex. Significant main effects of PSS scores ($P = .003$) and rs9296158 ($P = .007$) and significant interaction between the 2 ($P = .002$) on baseline cortisol levels were observed. Post-traumatic stress disorder symptom severity was negatively correlated with baseline cortisol level only in individuals carrying rs9296158 GG (Pearson correlation = -0.328 for GG and 0.157 for AA/AG, both significant at $P = .01$) (Figure 1A). The association remained significant after correcting for possible confounding effects of child abuse and adult trauma severity (PSS scores: $P = .03$; rs9296158: $P = .04$; and PSS score \times rs9296158: $P = .02$). Overall, *FKBP5* genotype was not associated with the level of child abuse ($P = .55$).

Dexamethasone Suppression Test—Using repeated-measures analysis of variance, we next investigated the interaction of rs9296158 A carrier status and PTSD status on cortisol suppression. We confirmed a significant triple interaction of the genotype and PTSD on the change in cortisol levels ($P = .03$; $F_{114,1} = 4.963$).

We observed a significant PTSD status \times rs9296158 genotype carrier status interaction ($P = .04$), but no main genotype or disease effect, on the change in cortisol levels. As observed before, PTSD was associated with increased dexamethasone suppression only in risk allele A carriers. The triple interaction of the genotype and PTSD status on cortisol suppression remained significant after adjusting for child abuse and adult trauma ($P = .04$) (Figure 1B).

MAIN EFFECTS OF PTSD SYMPTOM SEVERITY ON GENE EXPRESSION IN THE ATLANTA COHORT

To analyze the effects of PTSD symptom severity on gene expression, the continuous PSS scores were regressed against the filtered 15 583 expression profiles. After age and sex adjustment and multiple testing correction using the permutation of regressor residuals, 183

transcripts were significant with P values $<.01$, none of which had been previously reported to be associated with PTSD. Of these, 85 transcripts remained significant after adjusting for possible confounding effects of child abuse and adult trauma (eTable 3 and eFigure 2).

INTERACTION OF *FKBP5* SNP rs9296158 WITH PTSD SYMPTOM SEVERITY ON GENE EXPRESSION IN THE ATLANTA COHORT

To investigate whether the observed *FKBP5* genotype-dependent difference in GR sensitivity in PTSD would influence gene expression patterns, we used linear regression analyses to test the contribution of the continuous PTSD symptom severity, rs9296158 A carrier status, and their interaction to expression levels. Forty-one transcripts were significant for the genotype \times PTSD symptom interaction after correcting for multiple testing using the permutation of regressor residuals test and an interaction P value of $<.05$ (Table 2 and eFigure 3). Nine of these 41 transcripts had already been identified using only PTSD symptoms as a predictor as described earlier, so that 32 novel transcripts were identified using this model. These 32 genes included *FKBP5* and *IL18R1*, where either the molecule itself or the ligand had previously been reported to be regulated by PTSD.^{42–44}

Pathway Analysis—Analysis of gene expression data in the form of gene networks can provide a more comprehensive view of gene interactions underlying complex traits of interest.⁴⁵ To investigate possible common components of regulatory pathways, the 41 transcripts were characterized using the BiblioSphere software.³⁷ Pathway analysis of these 41 transcripts revealed a network that directly included 15 of the tested genes as well as associated transcription factors. These included *CREB1*, *HDAC1*, *FOS*, and *STAT5B*, which had previously been reported to be associated with PTSD symptoms^{42,43} (eFigure 4). In fact, *STAT5B* expression showed a significant correlation with *FKBP5* expression in this data set, with a Pearson correlation of 0.25 and 2-tailed significance of $P=.007$.

Analysis of Transcription Factor Binding Sites—We next investigated the distribution of steroid hormone binding sites, including GR response elements, androgen receptor response elements, and progesterone receptor response elements, within the 32 transcripts regulated by the SNP \times PTSD symptom interaction vs the 183 transcripts associated with PTSD symptom severity alone. For this, the JASPAR CORE database was probed to test for a possible overrepresentation of these steroid receptor response elements. Comparisons between the 183 transcripts identified using the PTSD symptom scores and 32 transcripts significant for the rs9296158 \times PSS score interaction revealed a highly significant overrepresentation of steroid response elements (GR response elements and androgen receptor response elements) among the 32 transcripts but not the 183 transcripts associated with PTSD symptom severity alone (eTable 4). No progesterone receptor response elements were predicted in any of the tested transcripts.

qPCR VALIDATION OF *FKBP5* AND *IL18R1* EXPRESSION

Because *FKBP5* and *IL18* had been reported in previous PTSD gene expression studies, we proceeded to validate *FKBP5* and *IL18R1* expression results in the 111 individuals from the microarray analysis using qPCR. For both *FKBP5* and *IL18R1*, significant main effects for PSS score as well as significant interaction between PSS and rs9296158 were observed (*FKBP5*: PSS total score, $P=.002552$; PSS score \times rs9296158, $P=.006932$; *IL18R1*: PSS total score, $P=.012253$; PSS score \times rs9296158, $P=.018549$) in the qPCR data set.

qPCR REPLICATION OF *FKBP5* AND *IL18R1* EXPRESSION

Next, we proceeded to replicate our findings in an additional set of 98 individuals not used in the microarray analysis. We replicated the significant main effects for PSS score as well

as the significant interaction between the 2 for *FKBP5* and *IL18R1* after adjusting for age and sex in the independent replication sample (*FKBP5*: PSS total score, $P=.01967$; PSS score \times rs9296158, $P=.00319$; *IL18R1*: PSS total score, $P=.03826$; PSS score \times rs9296158, $P=.00408$).

The genotype-dependent differences in correlation of *FKBP5* messenger RNA levels and PSS score severity in the microarray data set, the qPCR validation, and the replication data set are depicted in Figure 2.

COMMENT

These data from endocrine measures as well as gene expression profiling suggest that the functional *FKBP5* polymorphism rs9296158 is not only associated with an increased risk for PTSD following childhood trauma^{10,11} but might also define biologically distinct subtypes of this disorder. Endocrine measures and gene expression data were available in more than 200 traumatized individuals. In fact, we could replicate that only risk allele carriers of this SNP show the previously reported association of GR supersensitivity with PTSD.^{10,13} On the other hand, baseline cortisol levels were decreased in PTSD only in patients with the nonrisk GG genotype. This suggests that the inheritance of GR sensitivity–moderating *FKBP5* polymorphisms^{10,22} can determine specific types of HPA-axis dysfunction within PTSD that were also reflected in gene-expression changes of a subset of GR-responsive genes.

A number of studies have reported both decreased baseline cortisol levels as well as increased GR sensitivity⁴⁶ in patients with PTSD, although the findings are not uniformly consistent across studies.^{14,17,47} While we also observed these 2 endocrine features with PTSD, these findings are restricted to specific *FKBP5* SNP genotype groups, which might be an explanation for some of the inconsistent findings in the literature. In this article, we replicated a relative GR resistance in nonaffected individuals carrying the risk allele, which is in line with our previous report.¹⁰ These data also support the previously reported decrease in negative feedback capacity in these individuals.²³ Also, as previously reported, the genotype-dependent association with GR function seems to be state dependent, with increased GR sensitivity in risk allele carriers with PTSD. We are currently investigating the molecular basis of this state dependence and speculate that in addition to possible expression changes of other GR chaperones and other systems influencing the HPA axis, this might be mediated by epigenetic changes. Interestingly, the protective genotype, not the risk, was associated with decreasing baseline cortisol levels with increasing PTSD symptoms. In our sample, decreased baseline cortisol level and increasing GR sensitivity therefore do not seem to be strongly correlated, suggesting that other mechanisms besides efficiency of negative feedback of the HPA axis, possibly including stress reactivity, regulate baseline cortisol levels in PTSD. The possibility that these 2 measures are somewhat disjunct is also supported by the fact that while the finding of increased GR sensitivity is relatively consistent across studies, it is less so for baseline cortisol changes, with decreases, no changes, and increases reported in PTSD.^{16,48} A previous study had also reported that PTSD-related decreases in baseline cortisol level might be dependent on a functional GR polymorphism, a possible additional confounder in this association.⁴⁹

The genotype-dependent endocrine differences with PTSD symptoms were also paralleled by genotype-dependent differences in whole-blood gene expression pattern, where expression levels of 183 transcripts were significantly associated with PTSD symptoms alone. Within these, none had been previously identified to be associated with PTSD. Adding the *FKBP5* polymorphism to the model identified 32 transcripts not detected in the first model that showed a significant interaction between *FKBP5* genotype and PTSD

symptom severity. In fact, these transcripts showed strong genotype-dependent differences for the correlation of gene expression levels with PTSD symptom severity (eFigure 3), which likely has precluded their identification when analyzing the association with PTSD symptom severity alone. Among the top transcripts exhibiting the most significant gene expression interaction effects was *FKBP5* itself. This is not surprising given the previously discussed influence of PTSD and *FKBP5* on GR function and the fact that *FKBP5* appears to be one of the most sensitive readouts of GR stimulation. *FKBP5* has been shown to be one of the genes with the strongest induction by GR activation in a number of studies, including our own.^{50,51} Most notably, Yehuda and colleagues⁴³ have also described a downregulation of *FKBP5* gene expression in whole blood with PTSD, as we observed for rs9296158 GG carriers. Within these 32 genes, the *IL18R1* transcript is also an interesting candidate. Zieker et al⁴⁴ reported interleukin 18 to be differentially expressed in the peripheral blood of patients with PTSD, concordant with the differential regulation of its receptor *IL18R1* in our cohort.

We also found that 15 of the genes regulated by the interaction between *FKBP5* genotype and PTSD can be integrated into the same pathway (eFigure 4) using the BiblioSphere software.³⁷ When expanding the annotation to include related transcription factors, we identified another 4 previously reported PTSD candidates: *CREB1*, *FOS*, *HDAC1*, and *STAT5B*^{42,43} to be part of this common regulatory pathway. We could confirm the significant correlation between expression levels of *FKBP5* and *STAT5B* in this study, both of which had been previously shown to be regulated with PTSD by Yehuda et al.⁴³ Our data suggest that a data mining approach could be informative in revealing coexpressed gene networks and might help identify transcripts that otherwise would be missed when not passing statistical thresholds of significance because of the subtle gene expression differences.

While we did identify a number of genes regulated by PTSD symptom severity itself, our data suggest that a network of genes is differentially regulated depending on *FKBP5* genotype and related differences in GR sensitivity. In fact, there was a significant overrepresentation of GR response elements and androgen receptor response elements among these 32 transcripts significant for the interaction term compared with the 183 genes regulated by PTSD alone. Altogether, these findings suggest that the combined model of *FKBP5* SNP genotype and PTSD symptoms seems most relevant for GR-dependent transcripts, while other predictive models might be necessary to capture differences in the expression of other gene classes.

While we were able to replicate some of the genes and pathways identified in previous studies, others could not be replicated. This is likely because of a number of reasons, including false-positive and false-negative associations in either study, differences in clinical study design, sample characteristics, type of microarrays, and statistical analysis.

A strength of our microarray gene expression study (n=111 in total) is the large sample size, with 41 individuals with a probable PTSD diagnosis, which, to our knowledge, is larger than any of the previously reported expression array studies for this disorder. In the overall sample, we investigated 75 individuals with a probable PTSD diagnosis. We acknowledge that our main PTSD definition is symptom driven; using the PSS might have included individuals with other anxiety disorders also showing high PSS scores.⁵² However, about 70% of our cohort had CAPS-based current PTSD diagnoses and these concurred well with the PSS scores (Pearson $r=0.657$, significant at a $P=.01$). The use of the PSS allowed us to include all individuals and to increase the power of the study by using a quantitative predictor vs using diagnostic cutoffs, a strategy now advocated by a number of investigators for biomarker discovery.^{42,53} A limitation of this highly traumatized sample is the

heterogeneity regarding the timing of the trauma as well as the types of traumatic events. Despite this, our gene expression results appear to be comparable with other studies with much more defined index trauma, as described earlier.^{16,42}

In this sample, all subjects had experienced at least 1 significant trauma; nonetheless, we noted significant differences in overall trauma exposure as well as the level of child abuse between individuals with high vs low PTSD symptoms. When correcting the analysis for adult trauma and child abuse exposure, about 50% of the associations with PTSD severity alone remained significant at a level of $P=.05$, indicating the importance of increased trauma exposure on gene expression, even when using traumatized individuals as controls (eTable 3). Differences in severity and timing of trauma exposure might also account for the slight differences in the PTSD×SNP interaction on *FKBP5* messenger RNA expression in the discovery vs the replication sample (Figure 2 and eTable 1).

Independent replication is extremely important to assess the validity of gene expression findings, because more often than not specific changes reported for psychiatric disorders could not be replicated.^{54,55} In this study, we chose *FKBP5* and *IL18R1* for validation and replication, because they had previously been implicated in this disorder. We could, in fact, validate and replicate the association with genotype-dependent gene expression differences of both 2 transcripts using qPCR.

In summary, using a large sample of 219 traumatized individuals, we examined the effects of *FKBP5* rs9296158 genotype, previously reported to increase the risk for PTSD with early trauma, on putative biomarkers for this disorder. In this study, we found that rs9296158 may be used to identify biologically different subtypes of PTSD in that the genotype groups differed with respect to PTSD-related changes in GR sensitivity. This was reflected in genotype- and PTSD-dependent differences in the expression of GR-dependent transcripts in whole blood. Our findings support the importance of using genetic markers and biological measures to increase the predictive validity of biomarkers in psychiatric disorders.⁵⁶

Acknowledgments

Funding/Support: This work was supported by the Max Planck Society and National Institute of Mental Health grant MH071537. Dr Bradley receives grant support or has received awards from the American Foundation for Suicide Prevention and the American Psychoanalytic Association Psychoanalytic Research Fund. Within the last 3 years, Dr Ressler has received research funding support from the National Institute of Mental Health, the National Institute on Drug Abuse, the Burroughs Wellcome Foundation, and the National Alliance for Research on Schizophrenia and Depression. Dr Binder has current grant support from the National Institute of Mental Health and the Doris Duke Charitable Foundation.

References

1. Breslau N. The epidemiology of posttraumatic stress disorder: what is the extent of the problem? *J Clin Psychiatry*. 2001; 62(suppl 17):16–22. [PubMed: 11495091]
2. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. *Arch Gen Psychiatry*. 1995; 52 (12):1048–1060. [PubMed: 7492257]
3. Koenen KC, Lyons MJ, Goldberg J, Simpson J, Williams WM, Toomey R, Eisen SA, True W, Tsuang MT. Co-twin control study of relationships among combat exposure, combat-related PTSD, and other mental disorders. *J Trauma Stress*. 2003; 16(5):433–438. [PubMed: 14584626]
4. Stein MB, Jang KL, Livesley WJ. Heritability of social anxiety-related concerns and personality characteristics: a twin study. *J Nerv Ment Dis*. 2002; 190(4):219–224. [PubMed: 11960082]
5. True WR, Rice J, Eisen SA, Heath AC, Goldberg J, Lyons MJ, Nowak J. A twin study of genetic and environmental contributions to liability for posttraumatic stress symptoms. *Arch Gen Psychiatry*. 1993; 50(4):257–264. [PubMed: 8466386]

6. Comings DE, Muhleman D, Gysin R. Dopamine D2 receptor (DRD2) gene and susceptibility to posttraumatic stress disorder: a study and replication. *Biol Psychiatry*. 1996; 40(5):368–372. [PubMed: 8874837]
7. Gelernter J, Southwick S, Goodson S, Morgan A, Nagy L, Charney DS. No association between D2 dopamine receptor (DRD2) “A” system alleles, or DRD2 haplotypes, and posttraumatic stress disorder. *Biol Psychiatry*. 1999; 45(5):620–625. [PubMed: 10088049]
8. Segman RH, Cooper-Kazaz R, Macciardi F, Goltser T, Halfon Y, Dobroborski T, Shalev AY. Association between the dopamine transporter gene and posttraumatic stress disorder. *Mol Psychiatry*. 2002; 7(8):903–907. [PubMed: 12232785]
9. Koenen KC, Aiello AE, Bakshis E, Amstadter AB, Ruggiero KJ, Acierno R, Kilpatrick DG, Gelernter J, Galea S. Modification of the association between serotonin transporter genotype and risk of posttraumatic stress disorder in adults by county-level social environment. *Am J Epidemiol*. 2009; 169(6):704–711. [PubMed: 19228812]
10. Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, Tang Y, Gillespie CF, Heim CM, Nemeroff CB, Schwartz AC, Cubells JF, Ressler KJ. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. *JAMA*. 2008; 299(11):1291–1305. [PubMed: 18349090]
11. Xie P, Kranzler HR, Poling J, Stein MB, Anton RF, Farrer LA, Gelernter J. Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. *Neuropsychopharmacology*. 2010; 35(8):1684–1692. [PubMed: 20393453]
12. de Kloet ER, Joëls M, Holsboer F. Stress and the brain: from adaptation to disease. *Nat Rev Neurosci*. 2005; 6(6):463–475. [PubMed: 15891777]
13. Yehuda R, Yang RK, Buchsbaum MS, Golier JA. Alterations in cortisol negative feedback inhibition as examined using the ACTH response to cortisol administration in PTSD. *Psychoneuroendocrinology*. 2006; 31(4):447–451. [PubMed: 16364555]
14. Mason JW, Giller EL, Kosten TR, Ostroff RB, Podd L. Urinary free-cortisol levels in posttraumatic stress disorder patients. *J Nerv Ment Dis*. 1986; 174(3):145–149. [PubMed: 3950596]
15. Yehuda R. Neuroendocrine aspects of PTSD. *Handb Exp Pharmacol*. 2005; (169):371–403. [PubMed: 16594265]
16. Yehuda R, Bierer LM, Sarapas C, Makotkine I, Andrew R, Seckl JR. Cortisol metabolic predictors of response to psychotherapy for symptoms of PTSD in survivors of the World Trade Center attacks on September 11, 2001. *Psychoneuroendocrinology*. 2009; 34(9):1304–1313. [PubMed: 19411143]
17. Yehuda R, Southwick SM, Nussbaum G, Wahby V, Giller EL Jr, Mason JW. Low urinary cortisol excretion in patients with posttraumatic stress disorder. *J Nerv Ment Dis*. 1990; 178(6):366–369. [PubMed: 2348190]
18. Grad I, Picard D. The glucocorticoid responses are shaped by molecular chaperones. *Mol Cell Endocrinol*. 2007; 275(1–2):2–12. [PubMed: 17628337]
19. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. *Endocr Rev*. 1997; 18(3):306–360. [PubMed: 9183567]
20. Scammell JG, Denny WB, Valentine DL, Smith DF. Overexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticoid resistance in three New World primates. *Gen Comp Endocrinol*. 2001; 124(2):152–165. [PubMed: 11703081]
21. Wozniak GM, Rüegg J, Abel GA, Schmidt U, Holsboer F, Rein T. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. *J Biol Chem*. 2005; 280(6):4609–4616. [PubMed: 15591061]
22. Binder EB, Salyakina D, Lichtner P, Wozniak GM, Ising M, Pütz B, Papiol S, Seaman S, Lucae S, Kohli MA, Nickel T, Künzel HE, Fuchs B, Majer M, Pfennig A, Kern N, Brunner J, Modell S, Baghai T, Deiml T, Zill P, Bondy B, Rupprecht R, Messer T, Köhnlein O, Dabitz H, Brückl T, Müller N, Pfister H, Lieb R, Mueller JC, Löhmusaar E, Strom TM, Bettecken T, Meitinger T, Uhr M, Rein T, Holsboer F, Muller-Myhsok B. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. *Nat Genet*. 2004; 36(12):1319–1325. [PubMed: 15565110]

23. Ising M, Depping AM, Siebertz A, Lucae S, Unschuld PG, Kloiber S, Horstmann S, Uhr M, Müller-Myhsok B, Holsboer F. Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. *Eur J Neurosci*. 2008; 28(2):389–398. [PubMed: 18702710]
24. Gillespie CF, Bradley B, Mercer K, Smith AK, Conneely K, Gapen M, Weiss T, Schwartz AC, Cubells JF, Ressler KJ. Trauma exposure and stress-related disorders in inner city primary care patients. *Gen Hosp Psychiatry*. 2009; 31(6):505–514. [PubMed: 19892208]
25. Gillespie CF, Phifer J, Bradley B, Ressler KJ. Risk and resilience: genetic and environmental influences on development of the stress response. *Depress Anxiety*. 2009; 26(11):984–992. [PubMed: 19750552]
26. Jovanovic T, Blanding NQ, Norrholm SD, Duncan E, Bradley B, Ressler KJ. Childhood abuse is associated with increased startle reactivity in adulthood. *Depress Anxiety*. 2009; 26(11):1018–1026. [PubMed: 19691032]
27. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Light-foot S, Menzel W, Granzow M, Ragg T. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. *BMC Mol Biol*. 2006; 7:3. [PubMed: 16448564]
28. Foa EB, Tolin DF. Comparison of the PTSD Symptom Scale-Interview Version and the Clinician-Administered PTSD scale. *J Trauma Stress*. 2000; 13(2):181–191. [PubMed: 10838669]
29. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Klauminzer G, Charney DS, Keane TM. A clinician rating scale for assessing current and lifetime PTSD: the CAPS-1. *Behav Therapist*. 1990; 13:187–188.
30. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry*. 1961; 4:561–571. [PubMed: 13688369]
31. Hovens JE, Bramsen I, van der Ploeg HM, Reuling IE. Test-retest reliability of the trauma and life events self-report inventory. *Psychol Rep*. 2000; 87(3 pt 1):750–752. [PubMed: 11191382]
32. Bernstein DP, Stein JA, Handelsman L. Predicting personality pathology among adult patients with substance use disorders: effects of childhood maltreatment. *Addict Behav*. 1998; 23(6):855–868. [PubMed: 9801721]
33. Kellogg SH, McHugh PF, Bell K, Schluger JH, Schluger RP, LaForge KS, Ho A, Kreek MJ. The Kreek-McHugh-Schluger-Kellogg Scale: a new, rapid method for quantifying substance abuse and its possible applications. *Drug Alcohol Depend*. 2003; 69(2):137–150. [PubMed: 12609695]
34. Huber W, von Heydebreck A, Sülthmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. *Bioinformatics*. 2002; 18(suppl 1):S96–S104. [PubMed: 12169536]
35. Potter DM. A permutation test for inference in logistic regression with small- and moderate-sized data sets. *Stat Med*. 2005; 24(5):693–708. [PubMed: 15515134]
36. Wilcox RR, Keselman HJ, Muska J, Cribbie R. Repeated measures ANOVA: some new results on comparing trimmed means and means. *Br J Math Stat Psychol*. 2000; 53(pt 1):69–82. [PubMed: 10895523]
37. Krawetz, S.; Epple, A.; Scherf, M. *BiblioSphere: Hypothesis Generation in Regulatory Network Analysis*. *Bioinformatics for Systems Biology*. New York, NY: Humana Press; 2009. p. 401–412.
38. Scherf M, Epple A, Werner T. The next generation of literature analysis: integration of genomic analysis into text mining. *Brief Bioinform*. 2005; 6(3):287–297. [PubMed: 16212776]
39. Sandelin A, Alkema W, Engström P, Wasserman WW, Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. *Nucleic Acids Res*. 2004; 32(database issue):D91–D94. [PubMed: 14681366]
40. Ramakers C, Ruijter JM, Deprez RH, Moorman AF. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. *Neurosci Lett*. 2003; 339(1):62–66. [PubMed: 12618301]
41. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-ΔΔC_T} Method. *Methods*. 2001; 25(4):402–408. [PubMed: 11846609]
42. Segman RH, Shefi N, Goltser-Dubner T, Friedman N, Kaminski N, Shalev AY. Peripheral blood mononuclear cell gene expression profiles identify emergent post-traumatic stress disorder among trauma survivors. *Mol Psychiatry*. 2005; 10(5):500–513. 425. [PubMed: 15685253]

43. Yehuda R, Cai G, Golier JA, Sarapas C, Galea S, Ising M, Rein T, Schmeidler J, Müller-Myhsok B, Holsboer F, Buxbaum JD. Gene expression patterns associated with posttraumatic stress disorder following exposure to the World Trade Center attacks. *Biol Psychiatry*. 2009; 66(7):708–711. [PubMed: 19393990]
44. Zieker J, Zieker D, Jatzko A, Dietzsch J, Nieselt K, Schmitt A, Bertsch T, Fassbender K, Spanagel R, Northoff H, Gebicke-Haerter PJ. Differential gene expression in peripheral blood of patients suffering from post-traumatic stress disorder. *Mol Psychiatry*. 2007; 12(2):116–118. [PubMed: 17252001]
45. Rietkerk T, Boks MP, Sommer IE, de Jong S, Kahn RS, Ophoff RA. Network analysis of positional candidate genes of schizophrenia highlights myelin-related pathways. *Mol Psychiatry*. 2009; 14(4):353–355. [PubMed: 19308022]
46. Yehuda R. Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications. *Ann N Y Acad Sci*. 2006; 1071:137–166. [PubMed: 16891568]
47. Lemieux AM, Coe CL. Abuse-related posttraumatic stress disorder: evidence for chronic neuroendocrine activation in women. *Psychosom Med*. 1995; 57(2):105–115. [PubMed: 7792368]
48. Yehuda R. Status of glucocorticoid alterations in post-traumatic stress disorder. *Ann N Y Acad Sci*. 2009; 1179:56–69. [PubMed: 19906232]
49. Bachmann AW, Sedgley TL, Jackson RV, Gibson JN, Young RM, Torpy DJ. Glucocorticoid receptor polymorphisms and post-traumatic stress disorder. *Psychoneuroendocrinology*. 2005; 30(3):297–306. [PubMed: 15511603]
50. Vermeer H, Hendriks-Stegeman BI, van Suylekom D, Rijkers GT, van Buul-Offers SC, Jansen M. An in vitro bioassay to determine individual sensitivity to glucocorticoids: induction of FKBP51 mRNA in peripheral blood mononuclear cells. *Mol Cell Endocrinol*. 2004; 218(1–2):49–55. [PubMed: 15130510]
51. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS, Dao-Pick TP, Pantoja C, Erle DJ, Yamamoto KR, Fahy JV. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. *Proc Natl Acad Sci U S A*. 2007; 104(40):15858–15863. [PubMed: 17898169]
52. Engelhard IM, Arntz A, van den Hout MA. Low specificity of symptoms on the post-traumatic stress disorder (PTSD) symptom scale: a comparison of individuals with PTSD, individuals with other anxiety disorders and individuals without psychopathology. *Br J Clin Psychol*. 2007; 46(pt 4):449–456. [PubMed: 17535536]
53. Segman RH, Shalev AY. Genetics of posttraumatic stress disorder. *CNS Spectr*. 2003; 8(9):693–698. [PubMed: 15079143]
54. Drago A, De Ronchi D, Serretti A. Incomplete coverage of candidate genes: a poorly considered bias. *Curr Genomics*. 2007; 8(7):476–483. [PubMed: 19412419]
55. Hu FY, Hu WB, Liu L, Yu LH, Xi J, He XH, Zhu MR, Liu ZL, Xu YM. Lack of replication of a previously reported association between polymorphism in the 3' UTR of the alpha-synuclein gene and Parkinson's disease in Chinese subjects. *Neurosci Lett*. 2010; 479(1):31–33. [PubMed: 20478361]
56. Holsboer F. How can we realize the promise of personalized antidepressant medicines? *Nat Rev Neurosci*. 2008; 9(8):638–646. [PubMed: 18628772]




Figure 1.

Cortisol levels at baseline and after low-dose dexamethasone suppression. A, Baseline cortisol levels in individuals with and without posttraumatic stress disorder (PTSD) stratified by the rs9296158 A carrier status. In individuals carrying rs9296158 GG, PTSD symptom severity was negatively correlated with baseline cortisol level (Pearson correlation= -0.328), and in individuals carrying AA/AG, PTSD symptom severity was positively correlated with baseline cortisol level (Pearson correlation= 0.157). B, Levels of serum cortisol suppression after low-dose (0.5-mg) dexamethasone suppression in individuals with and without PTSD stratified by rs9296158 A carrier status. Posttraumatic stress disorder was associated with increased dexamethasone suppression only in risk allele A carriers. The triple interaction of rs9296158 A carrier status and PTSD status on cortisol suppression was significant ($P=.03$). To convert cortisol to nanomoles per liter, multiply by 27.588.




Figure 2.

Validation and replication of *FKBP5* expression differences in posttraumatic stress disorder (PTSD) using quantitative polymerase chain reaction (qPCR). The PTSD Symptom Scale (PSS) total scores are plotted on the x-axis against the expression levels as measured by log₂ expression for the microarray data and 2^{-ΔC_T} (change in crossing thresholds) for the qPCR validation and replication on the y-axis. The Pearson correlation coefficients for the rs9296158 A carrier status groups are shown. Post hoc genotype-dependent differences of the correlation coefficients were established by converting them into Fisher z scores.¹⁰ The z score differences between the 2 genotype groups were significant for the microarray expression ($z=2.17$; significant at $P=.01$), qPCR validation ($z=2.12$; significant at $P=.05$), and qPCR replication ($z=2.87$; significant at $P=.01$). RT-PCR indicates reverse transcriptase–polymerase chain reaction.

Table 1
 Comparison of 211 Individuals Used for Endocrine Analysis and 111 Individuals Used for Microarray Analysis^a

	Endocrine Analysis (n=211)			Microarray Analysis (n=111)		
	Non-PTSD (n=136)	PTSD (n=75)	P Value	Non-PTSD (n=70)	PTSD (n=41)	P Value
Age, y	43.28 (13.86)	40.12 (12.72)	.10	44.24 (13.24)	40.66 (12.72)	.17
Sex, No. (%)						
M	45 (33.1)	22 (29.3)	.34	21 (30.4)	11 (27.5)	.45
F	91 (66.9)	53 (70.7)		49 (69.6)	30 (72.5)	
Ethnicity, No. (%)						
African American or black	123 (90.4)	67 (89.3)	.80	64 (91.42)	35 (85.37)	.44
White	8 (5.9)	6 (8)		3 (4.29)	0	
Hispanic or Latino	2 (1.5)	0		1 (1.4)	4 (9.75)	
Mixed	2 (1.5)	1 (1.3)		1 (1.4)	2 (4.88)	
Unknown	1 (0.7)	1 (1.3)		1 (1.4)	0	
Trauma exposure						
TEI total trauma adult score	5.34 (3.9)	7.15 (3.58)	.001	3.0 (2.0)	4.0 (2.0)	.11
CTQ total score	39.03 (14.27)	49.96 (22.67)	<.001	39.18 (14.66)	49.58 (19.00)	.004
PSS total score	5.74 (5.93)	26.17 (9.85)	<.001	6.70 (6.69)	25.17 (9.70)	<.001
CAPS current trauma total score	24.53 (27.54)	68.50 (46.91)	<.001	25.78 (29.62)	67.89 (44.93)	<.001
CAPS lifetime trauma total score	59.2 (46.13)	106.43 (53.99)	<.001	64.90 (46.53)	109.46 (51.73)	<.001
BDI total score	9.82 (8.8)	22.69 (11.98)	<.001	10.49 (9.27)	22.72 (11.52)	<.001
Substance abuse current, No. (%)						
Yes	3 (2.2)	5 (6.7)	.11	23 (32.9)	17 (41.5)	.56
No	131 (97.8)	70 (93.3)		47 (67.1)	24 (58.5)	
Substance abuse past, No. (%)						
Yes	41 (30.8)	31 (41.3)	.09	3 (4.3)	4 (9.8)	.40
No	92 (69.2)	44 (58.7)		67 (95.7)	37 (90.2)	
KMSK alcohol current score	2.6 (3.7)	2.54 (3.5)	.93	2.5 (3.4)	1.87 (3.38)	.60
KMSK tobacco current score	1.79 (3.3)	3.21 (3.9)	.12	1.72 (3.4)	3.18 (4.1)	.27
KMSK cocaine current score	0.09 (0.61)	0.83 (2.7)	.10	0.22 (0.94)	0	.37

	Endocrine Analysis (n=211)			Microarray Analysis (n=111)		
	Mean (SD)		P Value	Mean (SD)		P Value
	Non-PTSD (n=136)	PTSD (n=75)		Non-PTSD (n=70)	PTSD (n=41)	
KMSK marijuana current score	1.0 (2.49)	1.0 (2.4)	>.99	1.056 (2.69)	1.067 (2.46)	.99
Day 1 cortisol level, µg/dL	15.37 (7.70)	15.61 (7.59)	.51	14.92 (7.61)	15.59 (7.47)	.65
Day 2 cortisol level, µg/dL	4.94 (6.01)	4.35 (4.77)	.59	4.97 (5.50)	5.46 (5.54)	.44

Abbreviations: BDI, Beck Depression Inventory; CAPS, Clinician-Administered PTSD Scale; CTQ, Childhood Trauma Questionnaire; KMSK, Kreek-McHugh-Schluger-Kellogg Scale; PSS, PTSD Symptom Scale; PTSD, posttraumatic stress disorder; TEL, Trauma Events Inventory.

SI conversion factor: To convert cortisol to nanomoles per liter, multiply by 27.588.

^aPhenotypic group comparisons between individuals in the PTSD and non-PTSD groups using the proxy PTSD variable among individuals used in the endocrine analysis (n=211) and individuals used in the microarray analysis (n=111). Group comparisons were calculated using analysis of variance, χ^2 test, or Fisher exact test.

Table 2

List of 41 Transcripts Significant for the Interaction Between PSS Score and rs9296158^a

Gene Symbol	Illumina ^b Probe ID	Significant With PSS Score Alone	Expression~PSS Score Pearson r		PSS Score x rs9296158 P Value		
			rs9296158 GG	rs9296158 AA/AG	ANOVA	Trauma Adjusted	Corrected
<i>P76</i>	ILMN_1734184	No	0.47817	-0.33669	.00015	.00043	.00020
<i>TK2</i>	ILMN_1766814	No	-0.76436	-0.02777	.00016	.00028	.00010
<i>CTSC</i>	ILMN_1696347	No	0.61956	-0.09383	.00031	.03900	.00020
<i>ODF2</i>	ILMN_1730698	No	0.49463	-0.14273	.00073	.09206	.00150
<i>GTPBP2</i>	ILMN_1694475	No	-0.59951	0.10253	.00081	.02476	.00070
<i>LOC643452</i>	ILMN_1682736	No	-0.56890	0.09748	.00086	.05438	.00130
<i>FKBP5</i>	ILMN_1778444	No	-0.49987	0.02563	.00282	.04444	.00330
<i>BIRC5</i>	ILMN_2349459	No	0.57429	0.05468	.00355	.03030	.00450
<i>MCMA4</i>	ILMN_2412860	Yes	0.50162	-0.03105	.00381	.03824	.00340
<i>C3orf1</i>	ILMN_2193175	No	-0.33791	0.30346	.00396	.07704	.00450
<i>EZH2</i>	ILMN_1708105	No	0.50143	-0.11772	.00488	.28239	.00480
<i>ZBTB16</i>	ILMN_2305407	No	-0.53328	-0.04405	.00673	.02190	.00720
<i>BHLHB2</i>	ILMN_1768534	No	0.35849	-0.18584	.00696	.13020	.00610
<i>LOC647460</i>	ILMN_1729198	No	-0.35417	0.30213	.00702	.02798	.00670
<i>FAM69A</i>	ILMN_1682577	No	-0.39838	0.22979	.00829	.05197	.00850
<i>C14orf80</i>	ILMN_1653553	No	0.53635	0.06719	.00975	.12307	.01200
<i>ZNF684</i>	ILMN_1751393	No	-0.26585	0.24363	.01053	.20257	.01420
<i>CAMK1D</i>	ILMN_1795561	Yes	0.19985	-0.37048	.01070	.02572	.01150
<i>GINS2</i>	ILMN_1809590	Yes	0.61090	0.18267	.01118	.00738	.01220
<i>ACOT7</i>	ILMN_1740265	No	0.65108	0.07385	.01519	.02759	.01630
<i>LOC647037</i>	ILMN_1761922	No	-0.18321	0.31981	.01595	.08595	.01530
<i>NUSAP1</i>	ILMN_1726720	Yes	0.53809	0.13494	.01635	.03178	.01580
<i>THAPI1</i>	ILMN_1780699	No	0.23107	-0.27642	.02019	.05254	.02370
<i>FAM108B1</i>	ILMN_1660440	No	-0.38296	0.00115	.02032	.00046	.02090
<i>BZWI</i>	ILMN_1793846	No	-0.13509	0.33007	.02387	.05116	.02280
<i>NXFI</i>	ILMN_2358652	Yes	0.11059	-0.34754	.02648	.03248	.02530
<i>PLA2G4C</i>	ILMN_1810191	No	0.32896	-0.08184	.02707	.01867	.02710

Gene Symbol	Illumina ^b Probe ID	Significant With PSS Score Alone	Expression-PSS Score Pearson <i>r</i>		PSS Score x rs9296158 P Value		
			rs9296158 GG	rs9296158 AA/AG	ANOVA	Trauma Adjusted	Corrected
<i>UGP2</i>	ILMN_2284181	No	-0.29111	0.32012	.02744	.04307	.03020
<i>CDC20</i>	ILMN_1663390	Yes	0.54947	0.14556	.02830	.02563	.02590
<i>PLAGL2</i>	ILMN_1786601	No	0.44579	-0.13340	.02920	.01518	.03030
<i>CASZ1</i>	ILMN_1655191	Yes	0.59386	0.16751	.03004	.13843	.03150
<i>CX3CR1</i>	ILMN_1745788	No	0.54696	0.04575	.03028	.06447	.02790
<i>POLDP3</i>	ILMN_1685845	No	-0.46645	-0.00050	.03377	.07222	.03100
<i>ZBTB16</i>	ILMN_2402817	No	-0.45215	-0.08603	.03660	.00956	.03660
<i>SLC25A43</i>	ILMN_1662097	No	-0.28835	0.12678	.03810	.04372	.04030
<i>ASPM</i>	ILMN_1815184	No	0.42272	-0.03327	.03870	.40102	.04000
<i>NCOA6IP</i>	ILMN_1651506	Yes	0.04771	0.40608	.04086	.00212	.04030
<i>SLC8A3</i>	ILMN_1712023	Yes	-0.09220	-0.40295	.04144	.08910	.04210
<i>GCLM</i>	ILMN_1788547	No	0.13927	-0.24781	.04240	.01150	.04300
<i>CCNF</i>	ILMN_1773119	No	0.57323	0.05194	.04625	.16164	.04220
<i>IL18R1</i>	ILMN_1781700	No	-0.33430	-0.06447	.04906	.07070	.05000

Abbreviations: ANOVA, analysis of variance; PSS, PTSD Symptom Scale; ~, described by.

^aList of 41 transcripts significant for the interaction between PSS score and rs9296158 after adjusting for age and sex. The transcripts were corrected for multiple testing using the permutation of regressor residuals test. The Pearson correlation coefficient between the transcript expression levels and the continuous PSS score is indicated across all individuals stratified by the rs9296158 A carrier status groups.

^bIllumina, San Diego, California.